查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889414

奈米免疫療法遞送市場預測至2032年：按奈米載體類型、標靶化機制、治療方式、給藥途徑、最終用戶和地區分類的全球分析

Nano-Immunotherapy Delivery Market Forecasts to 2032 - Global Analysis By Nanocarrier Type, Targeting Mechanism, Therapeutic Modality, Administration Route, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球奈米免疫療法遞送市場價值將達到 31 億美元，到 2032 年將達到 38 億美元，在預測期內以 3% 的複合年成長率成長。

奈米免疫療法遞送系統利用奈米載體將免疫調節劑直接輸送到目標細胞和組織。這些載體通常是經過工程改造的奈米顆粒，能夠提高藥物穩定性、實現精準標靶化和可控釋放。透過將治療藥物集中於特定的免疫通路，它們可以增強療效並最大限度地減少副作用。潛在應用包括癌症治療、自體免疫疾病的調控、提升疫苗效力。奈米免疫療法遞送體現了奈米技術與免疫學的融合，能夠為複雜疾病的治療提供高度個人化和高效的干涉手段。

據癌症研究組織稱，脂質奈米顆粒遞送系統已在 mRNA 疫苗中成功應用，目前已成為標靶固態腫瘤免疫療法的領先平台，正在進行 120 多項臨床試驗。

對標靶免疫調節的需求日益成長

市場成長的驅動力在於對標靶免疫調節日益成長的需求，這種療法能夠精準控制癌症、自體免疫疾病和感染疾病中的免疫反應。奈米遞送系統可達到局部作用，提高治療效果，同時減少全身性副作用。奈米載體設計的進步，包括脂質奈米顆粒和聚合物系統，使得細胞激素、抗體和疫苗的個人化遞送成為可能。全球向精準醫療的轉型進一步強化了這項需求，使奈米免疫療法成為下一代醫療解決方案的關鍵工具。

奈米顆粒生物相容性的複雜性

奈米顆粒生物相容性的複雜性是其發展的主要阻礙因素。奈米載體必須能夠安全地與生物系統相互作用，同時避免免疫排斥、毒性或意外的生物分佈。在保持治療效果的同時實現體內穩定性需要精密的工程設計和廣泛的檢驗。由於長期安全性數據有限，監管障礙進一步阻礙了商業化進程。這些挑戰增加了研發成本，延緩了臨床應用，使得生物相容性成為奈米免疫療法在各種治療應用中大規模推廣應用的一大障礙。

免疫奈米載體平台的進展

免疫奈米載體平台的發展蘊藏著巨大的機遇，這些平台能夠實現多功能藥物、疫苗和遺傳物質的遞送。混合奈米載體、外泌體仿生系統和刺激響應型設計的創新正在拓展治療的可能性。這些平台可以同時標靶化免疫細胞、調節微環境並增強細胞內運輸。隨著研究的加速，免疫奈米載體有望徹底改變治療策略，並為癌症、感染疾病和自體免疫疾病提供更安全、更有效、更個人化的解決方案。

長期毒性方面的安全隱患

奈米顆粒的長期毒性引發了市場安全的擔憂。器官蓄積、意外的免疫反應以及慢性暴露的風險已引起監管機構和臨床醫生的警惕。由於縱向資料有限，難以全面評估其安全性，導致核准和廣泛應用延遲。大眾對奈米藥物安全性的認知也影響市場成長。透過嚴格的測試、透明的報告和先進的生物相容性設計來解決這些擔憂，對於降低風險和維持大眾對奈米免疫療法的信心至關重要。

新冠疫情的影響：

新冠疫情加速了奈米免疫療法遞送技術的應用，尤其是用於mRNA疫苗的脂質奈米顆粒。疫情表明，奈米載體平台具有擴充性、安全性和快速免疫接種的有效性。這項成功刺激了對奈米遞送技術的投資，以期將其應用於更廣泛的免疫療法領域。疫情過後，市場受益於人們對免疫調節的認知提高以及對未來疫情爆發的準備。這場危機最終增強了人們對奈米醫學的信心，並將奈米免疫療法遞送技術確立為現代醫療創新的基石。

預計在預測期內，脂質奈米顆粒（LNP）細分市場將佔據最大的市場佔有率。

由於脂質奈米顆粒（LNP）在疫苗遞送和治療應用方面已取得顯著成功，預計在預測期內，LNP細分市場將佔據最大的市場佔有率。 LNP具有良好的生物相容性、擴充性以及對核酸和蛋白質的高效封裝能力。其在新冠疫苗中的廣泛應用證明了其可靠性，並加速了其在腫瘤學和自體免疫疾病治療領域的應用。隨著市場對安全且用途廣泛的奈米載體的需求不斷成長，LNP將繼續保持領先地位，並在預測期內鞏固其作為市場佔有率最大貢獻者的地位。

預計在預測期內，活性配體介導的標靶治療領域將實現最高的複合年成長率。

由於其能夠將奈米載體精準靶向特定免疫細胞和組織，活性配體介導靶向技術預計將在預測期內實現最高成長率。連接抗體、胜肽和適配體等配體可增強治療效果並減少脫靶效應。配體設計和受體分析技術的進步正在拓展其在癌症免疫療法和自體免疫疾病管理中的應用。這種高特異性使得配體介導標靶技術成為奈米免疫療法遞送領域成長最快的細分市場。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這主要得益於其不斷完善的醫療基礎設施、日益​​普遍的慢性病以及政府對生物技術的大力支持。中國、日本和印度等國家正大力投資奈米醫學研究和臨床試驗。成本效益高的生產方式和不斷成長的患者群體進一步鞏固了該地區的優勢。隨著先進治療方法的日益普及，亞太地區將繼續保持其作為奈米免疫療法遞送領先中心的地位，推動大規模商業化並鞏固其市場領導地位。

複合年成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於先進的研發能力、健全的法規結構以及奈米醫學的早期應用。美國在免疫療法、臨床試驗和生技Start-Ups方面投入巨資，主導。癌症和自體免疫疾病的高發生率推動了精準醫療的需求。有利的報銷政策以及與醫療保健系統的整合將進一步促進成長。在創新和基礎設施的驅動下，北美有望成為奈米免疫療法遞送市場成長最快的地區。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，對主要國家的市場規模和複合年成長率進行估算和預測（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球奈米免疫療法遞送市場（以奈米載體類型分類）

  • 脂質奈米顆粒（LNPs）
  • 聚合物奈米粒子
  • 蛋白質/胜肽奈米載體
  • 無機奈米顆粒（金、二氧化矽）
  • 外泌體和囊泡遞送
  • 混合多功能奈米載體

6. 全球奈米免疫療法遞送市場按標靶化機制分類

  • 被動腫瘤標靶化（EPR效應）
  • 活性配體介導的靶向
  • 刺激響應釋放系統
  • 細胞定向遞送（抗原呈現細胞/T細胞）
  • 細胞內運輸促進劑
  • 免疫微環境調節因子

7. 全球奈米免疫療法遞送市場依治療方式分類

  • 癌症免疫療法遞送
  • 疫苗和佐劑遞送
  • 自體免疫調節療法
  • 過繼細胞治療支持系統
  • 基因編輯和基於RNA的免疫療法
  • 複合奈米治療平台

8. 全球奈米免疫療法遞送市場（依給藥途徑分類）

  • 靜脈輸液系統
  • 瘤內及局部給藥
  • 吸入和肺部給藥
  • 口腔和黏膜奈米遞送
  • 經皮微針平台
  • 嵌入式倉庫系統

9. 全球奈米免疫療法遞送市場（按最終用戶分類）

  • 製藥和生物技術公司
  • 學術和臨床研究中心
  • 醫院/腫瘤中心
  • 合約研發生產組織（CDMO）
  • 其他最終用戶

10. 全球奈米免疫療法遞送市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Moderna
  • BioNTech
  • Pfizer
  • AstraZeneca
  • Novartis
  • Sanofi
  • Johnson &Johnson
  • Gilead Sciences
  • Roche
  • Merck
  • Bayer
  • Takeda
  • BD Biosciences
  • Thermo Fisher Scientific
  • Danaher
  • Catalent
  • Evonik Health Care
  • Precision NanoSystems
Product Code: SMRC32787

According to Stratistics MRC, the Global Nano-Immunotherapy Delivery Market is accounted for $3.1 billion in 2025 and is expected to reach $3.8 billion by 2032 growing at a CAGR of 3% during the forecast period. Nano-Immunotherapy Delivery systems use nanoscale carriers to transport immune-modulating agents directly to targeted cells or tissues. These carriers, often engineered nanoparticles, enhance drug stability, precision targeting, and controlled release. By focusing therapeutic payloads on specific immune pathways, they improve efficacy while minimizing side effects. Applications include cancer treatment, autoimmune regulation, and vaccine enhancement. Nano-immunotherapy delivery represents a fusion of nanotechnology and immunology, enabling highly personalized and efficient interventions in complex disease management.

According to the Cancer Research Institute, lipid nanoparticle delivery systems, proven by their success in mRNA vaccines, are now the leading platform for targeted solid-tumor immunotherapy, with over 120 clinical trials currently underway.

Market Dynamics:

Driver:

Rising demand for targeted immunomodulation

The market is driven by increasing demand for targeted immunomodulation, enabling precise control of immune responses in cancer, autoimmune, and infectious diseases. Nano-delivery systems allow localized action, reducing systemic side effects and improving therapeutic efficacy. Advances in nanocarrier design, including lipid nanoparticles and polymeric systems, support tailored delivery of cytokines, antibodies, and vaccines. This demand is reinforced by the global shift toward precision medicine, positioning nano-immunotherapy as a critical tool for next-generation healthcare solutions.

Restraint:

Complexity of nanoparticle biocompatibility

A major restraint is the complexity of ensuring nanoparticle biocompatibility. Nano-carriers must interact safely with biological systems, avoiding immune rejection, toxicity, or unintended biodistribution. Achieving stability in vivo while maintaining therapeutic efficacy requires advanced engineering and extensive validation. Regulatory hurdles further complicate commercialization, as long-term safety data is limited. These challenges increase development costs and slow clinical adoption, making biocompatibility a critical barrier to scaling nano-immunotherapy delivery across diverse therapeutic applications.

Opportunity:

Advances in immune nanocarrier platforms

Significant opportunity lies in advances in immune nanocarrier platforms, which enable multifunctional delivery of drugs, vaccines, and genetic material. Innovations in hybrid nanocarriers, exosome-inspired systems, and stimuli-responsive designs are expanding therapeutic potential. These platforms can simultaneously target immune cells, modulate microenvironments, and enhance intracellular trafficking. As research accelerates, immune nanocarriers are poised to revolutionize treatment strategies, offering safer, more effective, and personalized solutions for oncology, infectious diseases, and autoimmune disorders.

Threat:

Safety concerns around long-term toxicity

The market faces threats from safety concerns related to long-term nanoparticle toxicity. Accumulation in organs, unforeseen immune reactions, and chronic exposure risks raise caution among regulators and clinicians. Limited longitudinal data makes it difficult to fully assess safety profiles, slowing approvals and adoption. Public perception of nanomedicine safety also influences market growth. Addressing these concerns through rigorous testing, transparent reporting, and advanced biocompatible designs is essential to mitigate risks and sustain confidence in nano-immunotherapy delivery.

Covid-19 Impact:

Covid-19 accelerated adoption of nano-immunotherapy delivery, particularly lipid nanoparticles used in mRNA vaccines. The pandemic validated nanocarrier platforms as scalable, safe, and effective for rapid immunization. This success boosted investment in nano-delivery technologies for broader immunotherapy applications. Post-pandemic, the market benefits from heightened awareness of immune modulation and preparedness for future outbreaks. The crisis ultimately strengthened confidence in nanomedicine, positioning nano-immunotherapy delivery as a cornerstone of modern healthcare innovation.

The lipid nanoparticles (LNPs) segment is expected to be the largest during the forecast period

The lipid nanoparticles (LNPs) segment is expected to account for the largest market share during the forecast period, driven by their proven success in vaccine delivery and therapeutic applications. LNPs offer biocompatibility, scalability, and efficient encapsulation of nucleic acids and proteins. Their widespread use in Covid-19 vaccines demonstrated reliability, accelerating adoption in oncology and autoimmune therapies. As demand for safe, versatile nanocarriers grows, LNPs remain the dominant choice, securing their position as the largest contributor to market share during the forecast period.

The active ligand-mediated targeting segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the active ligand-mediated targeting segment is predicted to witness the highest growth rate, propelled by its precision in directing nanocarriers to specific immune cells or tissues. By attaching ligands such as antibodies, peptides, or aptamers, these systems enhance therapeutic efficacy and reduce off-target effects. Advances in ligand engineering and receptor profiling are expanding applications in cancer immunotherapy and autoimmune disease management. This high specificity positions ligand-mediated targeting as the fastest-growing segment in nano-immunotherapy delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to expanding healthcare infrastructure, rising prevalence of chronic diseases, and strong government support for biotechnology. Countries like China, Japan, and India are investing heavily in nanomedicine research and clinical trials. Cost-effective manufacturing and growing patient populations further reinforce regional dominance. With increasing adoption of advanced therapies, Asia Pacific remains the leading hub for nano-immunotherapy delivery, driving large-scale commercialization and market leadership.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR supported by advanced R&D, strong regulatory frameworks, and early adoption of nanomedicine. The U.S. leads with robust investment in immunotherapy, clinical trials, and biotech startups. High prevalence of cancer and autoimmune disorders accelerates demand for precision therapies. Favorable reimbursement policies and integration with healthcare systems further strengthen growth. With innovation and infrastructure, North America is positioned as the fastest-growing region in the nano-immunotherapy delivery market.

Key players in the market

Some of the key players in Nano-Immunotherapy Delivery Market include Moderna, BioNTech, Pfizer, AstraZeneca, Novartis, Sanofi, Johnson & Johnson, Gilead Sciences, Roche, Merck, Bayer, Takeda, BD Biosciences, Thermo Fisher Scientific, Danaher, Catalent, Evonik Health Care, and Precision NanoSystems.

Key Developments:

In November 2025, Moderna unveiled its next-generation lipid nanoparticle (LNP) delivery platform for oncology immunotherapies. The innovation enables precise targeting of tumor microenvironments, offering rapid immune activation with improved safety profiles.

In October 2025, BioNTech launched its AI-enhanced nano-carrier system designed to optimize mRNA immunotherapy delivery. The system integrates adaptive algorithms to personalize dosing and improve therapeutic outcomes in cancer and autoimmune disorders.

In September 2025, Pfizer announced the rollout of its scalable nano-immunotherapy manufacturing suite to support global clinical trials. The facility focuses on advanced encapsulation technologies, ensuring consistent quality and faster translation from lab to patient care.

Nanocarrier Types Covered:

  • Lipid Nanoparticles (LNPs)
  • Polymeric Nanoparticles
  • Protein & Peptide-Based Nanocarriers
  • Inorganic Nanoparticles (Gold, Silica)
  • Exosome & Vesicle-Based Delivery
  • Hybrid Multifunctional Nanocarriers

Targeting Mechanisms Covered:

  • Passive Tumor Targeting (EPR Effect)
  • Active Ligand-Mediated Targeting
  • Stimuli-Responsive Release Systems
  • Cell-Directed Delivery (APCs/T Cells)
  • Intracellular Trafficking Enhancers
  • Immune Microenvironment Modulators

Therapeutic Modalities Covered:

  • Cancer Immunotherapy Delivery
  • Vaccine & Adjuvant Delivery
  • Autoimmune Modulation Therapies
  • Adoptive Cell Therapy Support Systems
  • Gene-Editing & RNA-based Immunotherapies
  • Combination Nanotherapy Platforms

Administration Routes Covered:

  • Intravenous Delivery Systems
  • Intratumoral & Localized Delivery
  • Inhalation & Pulmonary Delivery
  • Oral & Mucosal Nanodelivery
  • Transdermal & Microneedle Platforms
  • Implantable Depot Systems

End Users Covered:

  • Pharmaceutical & Biotech Companies
  • Academic & Clinical Research Centers
  • Hospitals & Oncology Centers
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nano-Immunotherapy Delivery Market, By Nanocarrier Type

  • 5.1 Introduction
  • 5.2 Lipid Nanoparticles (LNPs)
  • 5.3 Polymeric Nanoparticles
  • 5.4 Protein & Peptide-Based Nanocarriers
  • 5.5 Inorganic Nanoparticles (Gold, Silica)
  • 5.6 Exosome & Vesicle-Based Delivery
  • 5.7 Hybrid Multifunctional Nanocarriers

6 Global Nano-Immunotherapy Delivery Market, By Targeting Mechanism

  • 6.1 Introduction
  • 6.2 Passive Tumor Targeting (EPR Effect)
  • 6.3 Active Ligand-Mediated Targeting
  • 6.4 Stimuli-Responsive Release Systems
  • 6.5 Cell-Directed Delivery (APCs/T Cells)
  • 6.6 Intracellular Trafficking Enhancers
  • 6.7 Immune Microenvironment Modulators

7 Global Nano-Immunotherapy Delivery Market, By Therapeutic Modality

  • 7.1 Introduction
  • 7.2 Cancer Immunotherapy Delivery
  • 7.3 Vaccine & Adjuvant Delivery
  • 7.4 Autoimmune Modulation Therapies
  • 7.5 Adoptive Cell Therapy Support Systems
  • 7.6 Gene-Editing & RNA-based Immunotherapies
  • 7.7 Combination Nanotherapy Platforms

8 Global Nano-Immunotherapy Delivery Market, By Administration Route

  • 8.1 Introduction
  • 8.2 Intravenous Delivery Systems
  • 8.3 Intratumoral & Localized Delivery
  • 8.4 Inhalation & Pulmonary Delivery
  • 8.5 Oral & Mucosal Nanodelivery
  • 8.6 Transdermal & Microneedle Platforms
  • 8.7 Implantable Depot Systems

9 Global Nano-Immunotherapy Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotech Companies
  • 9.3 Academic & Clinical Research Centers
  • 9.4 Hospitals & Oncology Centers
  • 9.5 Contract Development & Manufacturing Organizations (CDMOs)
  • 9.6 Other End Users

10 Global Nano-Immunotherapy Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Moderna
  • 12.2 BioNTech
  • 12.3 Pfizer
  • 12.4 AstraZeneca
  • 12.5 Novartis
  • 12.6 Sanofi
  • 12.7 Johnson & Johnson
  • 12.8 Gilead Sciences
  • 12.9 Roche
  • 12.10 Merck
  • 12.11 Bayer
  • 12.12 Takeda
  • 12.13 BD Biosciences
  • 12.14 Thermo Fisher Scientific
  • 12.15 Danaher
  • 12.16 Catalent
  • 12.17 Evonik Health Care
  • 12.18 Precision NanoSystems

List of Tables

  • Table 1 Global Nano-Immunotherapy Delivery Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Nano-Immunotherapy Delivery Market Outlook, By Nanocarrier Type (2024-2032) ($MN)
  • Table 3 Global Nano-Immunotherapy Delivery Market Outlook, By Lipid Nanoparticles (LNPs) (2024-2032) ($MN)
  • Table 4 Global Nano-Immunotherapy Delivery Market Outlook, By Polymeric Nanoparticles (2024-2032) ($MN)
  • Table 5 Global Nano-Immunotherapy Delivery Market Outlook, By Protein & Peptide-Based Nanocarriers (2024-2032) ($MN)
  • Table 6 Global Nano-Immunotherapy Delivery Market Outlook, By Inorganic Nanoparticles (Gold, Silica) (2024-2032) ($MN)
  • Table 7 Global Nano-Immunotherapy Delivery Market Outlook, By Exosome & Vesicle-Based Delivery (2024-2032) ($MN)
  • Table 8 Global Nano-Immunotherapy Delivery Market Outlook, By Hybrid Multifunctional Nanocarriers (2024-2032) ($MN)
  • Table 9 Global Nano-Immunotherapy Delivery Market Outlook, By Targeting Mechanism (2024-2032) ($MN)
  • Table 10 Global Nano-Immunotherapy Delivery Market Outlook, By Passive Tumor Targeting (EPR Effect) (2024-2032) ($MN)
  • Table 11 Global Nano-Immunotherapy Delivery Market Outlook, By Active Ligand-Mediated Targeting (2024-2032) ($MN)
  • Table 12 Global Nano-Immunotherapy Delivery Market Outlook, By Stimuli-Responsive Release Systems (2024-2032) ($MN)
  • Table 13 Global Nano-Immunotherapy Delivery Market Outlook, By Cell-Directed Delivery (APCs/T Cells) (2024-2032) ($MN)
  • Table 14 Global Nano-Immunotherapy Delivery Market Outlook, By Intracellular Trafficking Enhancers (2024-2032) ($MN)
  • Table 15 Global Nano-Immunotherapy Delivery Market Outlook, By Immune Microenvironment Modulators (2024-2032) ($MN)
  • Table 16 Global Nano-Immunotherapy Delivery Market Outlook, By Therapeutic Modality (2024-2032) ($MN)
  • Table 17 Global Nano-Immunotherapy Delivery Market Outlook, By Cancer Immunotherapy Delivery (2024-2032) ($MN)
  • Table 18 Global Nano-Immunotherapy Delivery Market Outlook, By Vaccine & Adjuvant Delivery (2024-2032) ($MN)
  • Table 19 Global Nano-Immunotherapy Delivery Market Outlook, By Autoimmune Modulation Therapies (2024-2032) ($MN)
  • Table 20 Global Nano-Immunotherapy Delivery Market Outlook, By Adoptive Cell Therapy Support Systems (2024-2032) ($MN)
  • Table 21 Global Nano-Immunotherapy Delivery Market Outlook, By Gene-Editing & RNA-based Immunotherapies (2024-2032) ($MN)
  • Table 22 Global Nano-Immunotherapy Delivery Market Outlook, By Combination Nanotherapy Platforms (2024-2032) ($MN)
  • Table 23 Global Nano-Immunotherapy Delivery Market Outlook, By Administration Route (2024-2032) ($MN)
  • Table 24 Global Nano-Immunotherapy Delivery Market Outlook, By Intravenous Delivery Systems (2024-2032) ($MN)
  • Table 25 Global Nano-Immunotherapy Delivery Market Outlook, By Intratumoral & Localized Delivery (2024-2032) ($MN)
  • Table 26 Global Nano-Immunotherapy Delivery Market Outlook, By Inhalation & Pulmonary Delivery (2024-2032) ($MN)
  • Table 27 Global Nano-Immunotherapy Delivery Market Outlook, By Oral & Mucosal Nanodelivery (2024-2032) ($MN)
  • Table 28 Global Nano-Immunotherapy Delivery Market Outlook, By Transdermal & Microneedle Platforms (2024-2032) ($MN)
  • Table 29 Global Nano-Immunotherapy Delivery Market Outlook, By Implantable Depot Systems (2024-2032) ($MN)
  • Table 30 Global Nano-Immunotherapy Delivery Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Nano-Immunotherapy Delivery Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 32 Global Nano-Immunotherapy Delivery Market Outlook, By Academic & Clinical Research Centers (2024-2032) ($MN)
  • Table 33 Global Nano-Immunotherapy Delivery Market Outlook, By Hospitals & Oncology Centers (2024-2032) ($MN)
  • Table 34 Global Nano-Immunotherapy Delivery Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2024-2032) ($MN)
  • Table 35 Global Nano-Immunotherapy Delivery Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.